ALG 126101
Alternative Names: ALG-126101Latest Information Update: 12 Jul 2022
At a glance
- Originator Aligos Therapeutics
- Class Antivirals; Small interfering RNA
- Mechanism of Action Hepatitis B surface antigen expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hepatitis B
Most Recent Events
- 22 Jun 2022 Preclinical trials in Hepatitis B in USA (unspecified route)